Core Viewpoint - The approval of SYS6055 injection by the National Medical Products Administration (NMPA) marks a significant advancement for the company, as it is the first domestically approved in vivo CAR-T product for clinical trials in China [1] Group 1: Product Development - SYS6055 is developed to generate CAR-T cells targeting CD19 directly in vivo using a lentiviral vector, which allows for specific identification and elimination of target cells [1] - The product demonstrates significant tumor suppression effects and good safety profiles in preclinical studies, indicating its potential as a better treatment option for patients with B-cell lymphomas [1] Group 2: Market Potential - Compared to traditional CAR-T products, SYS6055 offers potential advantages in terms of cost, accessibility, and immediacy [1] - The approved clinical indication is for relapsed/refractory aggressive B-cell lymphoma, with potential applications for other CD19-positive B-cell malignancies and autoimmune diseases, highlighting its high clinical development value [1]
石药集团(01093)：SYS6055注射液在中国获临床试验批准